Compare Gold Fields Limited (GFI) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gold Fields Limited vs IDEXX Laboratories, Inc. — how do they compare? Gold Fields Limited trades at $32.2 (market cap $29.07B), while IDEXX Laboratories, Inc. trades at $574.15 (market cap $43.94B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Gold Fields Limited pays a 7.03% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| GFI | IDXX | |
|---|---|---|
Market Cap | $29.07B | $43.94B |
Sector | Basic Materials | Health |
52-Week High | $61.52 | $766.68 |
52-Week Low | $23.95 | $514.61 |
Enterprise Value | $30.51B | $44.84B |
Dividend Yield | 7.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gold Fields (GFI) trades at $32.28, down 3.15% today, amid a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 40.76% net income margin and 52.33% ROE, while valuation ratios like P/E of 8.37 suggest undervaluation. Recent earnings were mixed, with a Q1 2025 beat but Q2 and Q4 2025 misses, and cash flow trends improved significantly in 2025 projections. News highlights operational challenges from inflation and geopolitical factors, though long-term value arguments persist.
The outlook balances deep value against near-term headwinds. Analyst consensus leans bullish with a $52.75 price target, but technical weakness and cost pressures pose risks. Investment appeal hinges on execution of production targets and gold price stability, with high ROE supporting shareholder returns.
IDXX trades at $572.38, up 5.86% over 24 hours, with a neutral technical signal and strong fundamentals. The company reported Q1 2026 EPS of $3.47, beating estimates, and maintains robust profitability with a 24.63% net margin. Revenue growth accelerated to $4.3 billion in 2025, supported by innovation in veterinary diagnostics and AI integration. Cash flow from operations remains healthy at $1.18 billion, though net cash flow was negative $108 million due to financing activities.
Outlook is positive given consistent earnings beats and analyst consensus leaning buy (59% of ratings). Key risks include high valuation multiples (P/E 40.99) and competitive pressures in medical devices. The stock's proximity to its 52-week high suggests momentum but warrants caution on pullbacks. Institutional sentiment is bolstered by product expansions like taeniid tapeworm detection and SDMA integration for kidney disease screening.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
